Publications by authors named "Pierre Barthet"
Article Synopsis
- Periodontitis poses significant health risks, including tooth loss and aggravated chronic diseases, impacting overall health and quality of life.
- Effective periodontal treatment starts with etiological therapy, focusing on oral hygiene and managing risk factors to reduce bacterial load and inflammation.
- While non-surgical debridement is crucial for treatment, the use of adjunctive therapies is limited by a lack of clear clinical guidelines, highlighting the need for standardized research and ongoing patient monitoring.
The aim of this study was to analyze the link between oral microbiota and obesity in humans. We conducted a pilot study including 19 subjects with periodontitis divided into two groups: normo-weighted subjects (NWS) with a body mass index (BMI) between 20 and 25 ( = 9) and obese subjects (OS) with a BMI > 30 ( = 10). Obesity was associated with a poor oral health status characterized by an increased number of missing teeth and a higher score of periodontal-support loss associated with dysbiotic oral microbiota (39.
View Article and Find Full Text PDFObjectives: With 39,359 entries on PubMed, periodontal medicine has a prominent position in periodontal research. Good patient care requires well-advised physicians, and whereas the dental community is informed about the relationships between periodontal diseases (PDs) and an increasing number of systemic pathologies, we wondered whether general practitioners were too. Thus, we aimed to evaluate their knowledge of the links between periodontal and systemic diseases.
View Article and Find Full Text PDFObjectives: Previous studies have shown that metronidazole, alone or in combination with spiramycin (250 mg/1 500 000 units, three times/day), is an effective treatment for active periodontitis, although the dose of metronidazole currently used (750 mg/day) could provide concentrations in gingival crevice fluid that are too low for the MICs of the involved pathogens. This study tested the in vivo antibacterial efficacy of the currently used metronidazole dose (as contained in the fixed spiramycin/metronidazole combination) in patients with an active periodontitis, and of a high dose (1500 mg/day) of metronidazole alone.
Methods: We measured the MICs of spiramycin and metronidazole for the recovered pathogens and the gingival crevice fluid antibiotic concentrations of both antibiotics, and attempted to correlate them with bacterial eradication.